<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Summers, Jaye</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Dellon, Evan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Budesonide Shows Validated Promise in Patients With Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-07 10:43:03</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-16</style></pages><abstract><style  face="normal" font="default" size="100%">In a randomized placebo-controlled trial, adults and adolescents with active EoE both histologically and symptomatically were given either oral budesonide or placebo for 12 weeks. Using a validated symptom tool and biopsy data, the results suggest a significant improvement in both symptoms and histology among those in the budesonide group, with no impending safety signals.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>